SV Life Sciences is a leading international life sciences venture capital firm. SVLS affiliated funds have been investing in life sciences companies since the early 1980s and the firm closed its first dedicated life sciences fund in 1994.
The SVLS team manages five private venture capital funds with approximately $1.9 billion of capital under management. The firm employs a diversified strategy within life sciences in order to selectively capitalize on an expanding opportunity in biotech, medical devices and health-care services. SVLS has offices in Boston, London and San Francisco.
Entellus Medical - IPO - January 2015
SV Life Sciences Advisers notes that Entellus Medical successfully listed on NASDAQ on 29 January 2015 The business wire press release is below Nasdaq Welcomes Entellus Medical, Inc. (Nasdaq: ENTL) to The Nasdaq Stock Market NEW YORK, Jan. 29, 2015 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq:NDAQ) announced that trading of Entellus Medical, Inc. (Nasdaq:ENTL), a medical technology company, commenced on The Nasdaq Stock Market on January 29, 2015.
Sale of Convergence Pharmaceuticals - January 2015
SV Life Sciences Fund V notes that Biogen Idec (NASDAQ: BIIB) acquired Convergence from its owners, SV Life Sciences and others, for a possible total of $ 675m - $200m upfront and $475m of milestone based payments. Convergence Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for chronic pain.